Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on How Minzasolmin is Absorbed in the Body and its Safety in Healthy Adults

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on understanding how the body absorbs a medication called Minzasolmin when taken in different forms and how food might affect its absorption. The study involves healthy adults and aims to compare a new tablet form of Minzasolmin with an existing capsule form. The purpose is to estimate how much of the drug enters the bloodstream in these different forms and conditions.

Participants in the study will take Minzasolmin in both tablet and capsule forms. The study will observe how the drug is absorbed when taken on an empty stomach and after eating. This will help researchers understand the best way to take Minzasolmin for optimal absorption. The study will also monitor for any side effects that may occur during the trial.

The trial is designed to ensure the safety of participants while gathering important information about Minzasolmin. By comparing the different forms and conditions, researchers hope to determine the most effective way to administer the medication. The study will provide valuable insights into the drug's behavior in the body, contributing to its safe and effective use in the future.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be asked to sign an informed consent form. This form confirms that you understand the study and agree to participate.

    You must be between 18 and 55 years old, in good health, and meet specific weight and body mass index criteria.

  2. Step 2

    Initial assessment

    A medical evaluation will be conducted, including a review of your medical history, a physical examination, laboratory tests, and heart monitoring to ensure you are healthy.

  3. Step 3

    Medication administration

    You will receive two different forms of the medication minzasolmin: a film-coated tablet and a capsule.

    The study will assess how much of the medication enters your body when taken in these forms and how food affects this process.

  4. Step 4

    Taking the medication

    You will take the minzasolmin tablet and capsule orally. The study will involve taking the medication under both fasted and fed conditions to evaluate the effect of food.

    The exact dosage, frequency, and duration of administration will be provided by the study team.

  5. Step 5

    Monitoring and follow-up

    Throughout the study, your health will be closely monitored. This includes measuring the concentration of minzasolmin in your blood at various times.

    You will be observed for any side effects or adverse reactions to the medication.

  6. Step 6

    Completion of the study

    At the end of the study, a final assessment will be conducted to ensure your well-being.

    You will be informed about the study's findings and any relevant information regarding your participation.

Who can join the trial?

4 criteria

  • Participant must be between 18 to 55 years old at the time of signing the informed consent form.
  • Participants should be overtly healthy, meaning they should not have any noticeable health issues. This will be determined by a medical evaluation, which includes checking medical history, a physical examination, laboratory tests, and heart monitoring.
  • Body weight should be between 45 to 100 kg for females and 50 to 100 kg for males.
  • Body mass index (BMI) should be within the range of 18 to 30 kg/m2. BMI is a measure that uses your height and weight to work out if your weight is healthy.

Who cannot join the trial?

4 criteria

  • Participants must be healthy. This means they should not have any ongoing medical conditions.
  • Participants must be within a certain age range. This study is for adults only.
  • Both men and women can participate.
  • Participants should not be part of a vulnerable population. This means they should not be in a situation where they are unable to make decisions for themselves.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Minzasolmin is a medication being tested in this clinical trial. The study is looking at how well a new tablet form of Minzasolmin is absorbed by the body compared to an older form that comes as granules in a capsule. The trial also examines if eating food affects how the new tablet form of Minzasolmin is absorbed. This information helps researchers understand the best way to take Minzasolmin for it to work effectively in the body.

What is already known about the treatment

Minzasolmin – Minzasolmin is administered in tablet form and is being studied to understand how well it is absorbed by the body compared to an older capsule form, as well as how food might affect its absorption. Currently, Minzasolmin is in clinical trials and is not yet widely used in medical practice, with studies focusing on healthy participants to gather initial data. The main goal of these studies is to determine the best way to deliver the medication into the body. Minzasolmin's mechanism of action and pharmacological classification are not detailed in the available data, as the focus is on its absorption and the effect of food on its pharmacokinetics.

Investigated diseases

Healthy Participants – This term refers to individuals who do not have any diagnosed medical conditions or diseases. They exhibit normal physiological functions and are free from symptoms that would indicate illness. Healthy participants are often used in clinical trials to establish baseline data or to test the effects of new treatments without the interference of existing health issues. Their inclusion helps researchers understand how a treatment or drug behaves in the absence of disease. These individuals typically have normal ranges in vital signs, laboratory tests, and physical examinations. They serve as a control group to compare against participants with specific medical conditions.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase ITrial ID2024-511301-31-00Protocol codeUP0152Estimated enrolment18 patientsSponsorUCB Biopharma

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).